Ocugen, Inc. (OCGN) stock

OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30

$0.83−0.05 (-5.24%)

Close on Nov 13, 2026Market cap $280.72MP/E –Yield –

Ocugen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2022 it was -$88.59M.

Period	Period end	Value	Change
FY2022	Dec 31, 2022	-$88.59M	–
FY2021	Dec 31, 2021	-$57.80M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OCGN.

Revenue growth8.8% · median -13.1%

Operating margin-1564.3% · median -2760.0%

Net margin-1481.0% · median -2619.6%

Advertisement
300 × 250

See a number that looks wrong?